Showing 1 - 3 results of 3 for search 'Elzbieta Iskierka-Jażdżewska', query time: 0.03s Refine Results
  1. 1
    PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2)

    PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR... by Silvana Novelli, Ashish Risal, Manjusha Namuduri, Jingxian Cai, Melanie Ufkin, Min Zhu, Sushmita Mukherjee, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Elżbieta Iskierka-Jażdżewska

    Published 2023-08-01
    Get full text
    Article
  2. 2
    Pneumonia in patients with chronic lymphocytic leukemia treated with venetoclax‐based regimens: A real‐world analysis of Polish Adult Leukemia Group (PALG)

    Pneumonia in patients with chronic lymphocytic leukemia treated with venetoclax‐based regimens: A real‐world analysis of Polish Adult Leukemia Group (PALG) by Elżbieta Kalicińska, Paula Jablonowska‐Babij, Marta Morawska, Elżbieta Iskierka‐Jażdżewska, Joanna Drozd‐Sokolowska, Ewa Paszkiewicz‐Kozik, Łukasz Szukalski, Judyta Strzała, Urszula Gosik, Jakub Dębski, Iga Andrasiak, Anna Skotny, Krzysztof Jamroziak, Tomasz Wrobel

    Published 2025-02-01
    Get full text
    Article
  3. 3
    P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2

    P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2 by Jan Walewski, Tae Min Kim, Seok-Goo Cho, Isidro Jarque, Elżbieta Iskierka-Jażdżewska, Michelle Poon, H. Miles Prince, Sung Yong Oh, Francesca Lim, Cecilia Carmen Carpio Segura, Tran-Der Tan, Sabarish Ayyappan, Antonio Gutiérrez, Jingjin LI, Melanie Ufkin, Min Zhu, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Won-Seog Kim

    Published 2023-08-01
    Get full text
    Article

Search Tools: